In this captivating episode of "Science in Society," hosts Drew and Liv dive into the fascinating world of chemistry, community, and entrepreneurship with their special guest, Jamie Shah. Jamie is not just any guest; she's the driving force behind Chem-Impex, a renowned family-owned chemical supply company. Join Drew, Liv, and Jamie as they unravel the intriguing story of Chem Impex, a business rooted in family, science, and innovation. Discover the challenges and triumphs of running a family business and gain insights into the ever-evolving landscape of chemical supply. But this episode isn't just about chemicals and business; it's about the power of building a strong community in science. Jamie shares her experiences and perspectives on fostering connections within the scientific community and why collaboration is essential for advancing knowledge and discoveries.

So, if you've ever been curious about the world of chemistry, entrepreneurship, or the importance of community in science, this episode is a must-listen. Tune in to "Science in Society" to hear Jamie Shah's inspiring journey and the pivotal role Chem Impex plays in the world of chemistry and beyond. You can learn more about Chem Impex on its website and about Jamie from her LinkedIn. Additionally, you can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.

Have you ever left a plastic water bottle in a car on a hot summer day and returned to notice it tasted different? Does opening your windows on a pleasant day really feel like a breath of fresh air? If either of these apply to you, you have firsthand experience with environmental toxins affecting your everyday life.

This month, Drew & Liv have the privilege of chatting about all things environmental toxins and endocrine disruptors with Drs. Alison Neff & Vicki Mourikes. Throughout the discussion, you will learn about the most common ways in which endocrine disruptors enter our environment, some of the possible mechanisms through which these chemicals alter hormonal pathways, and great strategies you can implement to decrease your exposures. You can find the Instagram accounts mentioned during today’s episode here and here, and the Dirty Dozen 2023 list can be found here. If you are interested in learning more about this topic, Drs. Neff & Mourikes recommended reading one of two review articles published from their lab as a great way to get started. As always, you can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.

Dirty Dozen:

• https://www.ewg.org/foodnews/dirty-dozen.php

Instagrams:

• https://www.instagram.com/environmentaltoxinsnerd/
• https://www.instagram.com/environmentalworkinggroup/

Review Articles:

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743013/
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425478/

If you are anything like Drew & Liv, you have – at least once – been exasperated with the constantly changing nutritional recommendations originating from largely observational and retrospective studies. Additionally, if you have ever wanted to optimize your nutrition to improve your energy, performance, or recovery, you know that the more accurate and personalized information you can gather, the better off you will be.

In this episode, Drew & Liv sit down with Ari Tulla, co-founder & CEO of Elo Health. His company uses key biomarkers and cutting-edge AI to provide folks with customized supplements, and his mission is to transform food from the leading cause of disease to medicine. From listening, you will learn why Ari became so passionate about nutrition optimization, how Elo integrates various data modalities to optimize its clients' biomarkers, and the harrowing statistics showing us why we all need to pay closer attention to the food we are consuming.

You can learn more about Ari & Elo Health at Elo's website and on Ari’s LinkedIn.

Additionally, you can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.

Have you, a loved one, or a close friend had a run-in with cancer at some point? Chances are that the answer is yes. The more involved you were in the treatment process, the more you can appreciate the relative imperfections of currently-available treatment options, though they are steadily improving. In this episode, Drew & Liv sit down with Dr. Kevin Parker, CEO and co-founder of Cartography Biosciences, who is at the forefront of developing personalized cancer treatment regimens. In this episode, the three of them cover the history and development of cancer treatments, the greatest challenges that have slowed the personalization of individualized immunotherapies, and how Kevin thinks Cartography can overcome those obstacles to enter a new generation of cancer treatments. You can learn more about Cartography on their website, cartographybio.com, and LinkedIn.  

Additionally, you can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.

Did last month’s episode leave you wanting to learn more about the rapidly developing space of psychedelic compounds’ use in treating psychiatric conditions like Major Depressive Disorder, Generalized Anxiety Disorder and various addiction disorders? Drew & Liv had a feeling you would, so look no further than this episode, where they bring on Doug Drysdale, CEO of Cybin Inc., to discuss his company’s mission and progress in this space. Throughout this episode, you will learn how psilocybin and other psychedelics present a completely different approach to treating depression, the underlying neuroplasticity of mental health disorders, and how a treatment session within this paradigm differs from that of current standard of care.

You can learn more about Doug’s and Cybin’s work on Cybin’s website, cybin.com. Additionally, you can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.

Mental health has increasingly become the topic of discussion in recent years, and while we–as a society–have become better at recognizing the signs of mental health issues, have you ever wondered exactly what they are, how they are treated, and what happens if the tools available to us aren’t enough? You might be surprised to hear that–by some estimates–at least 30% of people diagnosed with depression are resistant to the current options we have. That’s where our guest, Dr. Charles Nemeroff, and his research on psychedelic compounds come into play. In this episode, you will learn about depression and PTSD, the prevalence of treatment-resistant depression, and the promising research around psilocybin and its future potential as a therapeutic. You can learn more about Dr. Nemeroff’s research on his website.

Additionally, you can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.

The National Mental Health Hotline: 1-866-903-3787

If you had to rank your favorite 3 superheroes, would Iron Man make your list? Have you ever wondered if there could one day be a real-life Tony Stark? This month’s guest, Pavle Jeremic, is trying to make that science fiction a reality. In this episode, you, along with Drew & Liv, will learn how Jeremic and his team at Aether plan to use chemistry, biology, engineering, and artificial intelligence to develop a toolkit of molecular assemblers capable of synthesizing any desired arrangement of atoms.

You can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans.

Did you know that there are over 100 types of hearing loss? Are you also aware that there exist exceptionally few therapeutic options for those affected by one of those conditions?

This month, Drew & Liv had the privilege of bringing on one of the people leading the charge to develop new therapeutics for hearing and balance loss: Dr. Laurence Reid, CEO of Decibel Therapeutics. Dr. Reid provides a behind-the-scenes look at hearing restoration development and how single-cell genomics in a laboratory can translate to giving a previously deaf person their ability to hear. In this episode, you will learn about Dr. Reid’s journey from scientist to CEO, how Deibel leverages single-cell genomics, and the importance of science communication.

You can follow Drew & Liv on Instagram @scienceinsociety to stay in the know on upcoming episodes, new content, and their ~nearly~ famous science shenanigans. To learn more about Dr. Reid’s work, you can visit the Decibel Therapeutics website, follow the company's Twitter, or check out their Linkedin.